Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
8 evidence topics · 5 sources
Darolutamide: class and labeled indications
Darolutamide: recommended dosage and concurrent androgen deprivation
Darolutamide: dosage modification for adverse reactions
Darolutamide: warnings and precautions
Darolutamide: dosage form and package
Darolutamide: wholesale acquisition cost filing with the California Department of Health Care Access and Information
| Field | Quoted record |
|---|---|
| Manufacturer name | “Bayer” |
| National drug code | “50419039501” |
| Drug product description | “Nubeqa 300 mg tab 120 count” |
| WAC effective date | “2026-01-01T00:00:00” |
| WAC increase amount (USD) | “847.20” |
| WAC after increase (USD) | “15100.80” |